Author Interviews, Breast Cancer, Dartmouth, Radiology / 27.01.2014

Michael Mastanduno Thayer School of Engineering, Dartmouth College 14 Engineering Dr. Hanover, NH 03755MedicalResearch.com Interview with: Michael Mastanduno Thayer School of Engineering, Dartmouth College 14 Engineering Dr. Hanover, NH 03755 MedicalResearch.com: What are the main findings of the study? Answer: The study was able to illustrate the design and clinical testing of an MRI breast coil for combined MRI and Near Infrared Spectroscopy. The coil was tested on 8 healthy volunteers spanning all bra cup sizes and mammographic density categories. In the past, MRI/NIRS imaging was only possible in C and D cup sized breasts. The system also will give researchers the ability to target lesions in hard-to-reach areas close to the chest wall. With the successful completion of this study, simultaneous MRI/NIRS is possible in all breast sizes, tissue compositions, and lesion locations. (more…)
Author Interviews, Melanoma / 26.01.2014

Robert O. Dillman, M.D., F.A.C.P. Executive Medical Director Hoag Institute for Research and Education Hoag Cancer InstituteMedicalResearch.com Interview with: Robert O. Dillman, M.D., F.A.C.P. Executive Medical Director Hoag Institute for Research and Education Hoag Cancer Institute MedicalResearch.com: What are the main findings of the study? Dr. Dillman: The main finding of this study is that among 149 metastatic melanoma patients treated with high-dose interleukin-2 (IL2), survival was much better in the subset of 32 patients who also were treated with patient-specific vaccines (that is active specific immunotherapy or ASI) that contained antigens from tumor cell lines derived from there own metastases that had been surgically resected. The 5-year survival rate from the date of starting IL2 was 39% in those receiving vaccine compared to 13% in those who did not (p<0.001). A number of studies have reported that a 5-year survival rate of 15% is typical for patients treated with IL2. The data also suggested that 5-year survival was better in the 25 patients who received the vaccine after, rather than before IL2 (46% vs 14%), p<0.001). Among the 32 ASI-treated patients, there was a trend for survival benefit for the 16 patients treated with autologous dendritic cells pulsed with antigens from the autologous melanoma cells and injected with granulocyte-macrophage colony stimulating factor (GM-CSF) compared to injections of irradiated tumor cells with or without GM-CSF (p=0.17) (more…)
Author Interviews, Breast Cancer / 26.01.2014

MedicalResearch.com Interview with: Deirdre McLaughlin PhD MAPS Associate Professor, Principal Research Fellow Centre for Longitudinal and Lifecourse Research and Janni Leung, BHS School of Population Health University of Queensland MedicalResearch.com: What are the main findings of the study? Answer: Breast cancer patients living in rural areas were diagnosed later than breast cancer patients living in urban areas. Evidence from Australia, Egypt, Italy, Canada, Poland, South Africa, Denmark, and parts of the United States indicated that patients residing in rural areas were more likely to be diagnosed with more advanced breast cancer. Our meta-analysis showed that rural breast cancer patients had 1.19 higher odds (95% confidence interval= 1.12-1.27) of diagnosis of a late stage breast cancer compared to urban breast cancer patients. (more…)
Author Interviews, Breast Cancer, Psychological Science, Radiation Therapy / 22.01.2014

Guy H. Montgomery, Ph.D. Director, Integrative Behavioral Medicine Program Cancer Prevention and Control Department of Oncological Sciences, Box 1130 Icahn School of Medicine at Mount Sinai New York, NY 10029-6574MedicalResearch.com Interview with: Guy H. Montgomery, Ph.D. Director, Integrative Behavioral Medicine Program Cancer Prevention and Control Department of Oncological Sciences Icahn School of Medicine at Mount Sinai New York, NY 10029-6574 MedicalResearch.com: What are the main findings of the study? Dr. Montgomery: A brief psychological intervention comprised of cognitive behavioral techniques and hypnosis (CBTH) reduced fatigue during, and for up to six months after, radiotherapy in breast cancer patients. (more…)
Author Interviews, Breast Cancer, Surgical Research / 17.01.2014

MedicalResearch.com Interview with: Dr. R.A. Badwe, MS Director, Tata Memorial Centre E. Borges Marg, Parel Mumbai 400 012 MedicalResearch.com: What are the main findings of the study? Answer: The trial was a randomized control study involving 350 women with per primum metastatic breast cancer. These women were divided into two groups from February 2005 to May 2013. One group underwent surgery and radiotherapy (LRT) (n=173) while another group of 177 women were spared these (no LRT). Both groups had undergone six successful rounds of chemotherapy before their recruitment into the trial. Women who underwent surgery had the primary breast tumour and lymph nodes removed, followed by locoregional radiation therapy. The primary endpoint of the study was overall survival (OS). At a median follow-up of 17 months, no difference was observed in OS between the groups; the OS rates were 19.2% and 20.5%, respectively, (HR = 1.04; 95%CI, 0.80-1.34; P = 0.79). The lack of a survival benefit is due to a trade-off between local control and distant disease progression. The results indicated that women who underwent surgery and had improved locoregional control and significantly worse distant progression-free survival compared with women who did not undergo surgery (HR = 1.41; 95% CI, 1.08-1.85; P = .01). Progression of distant disease was 42% more likely (P = .01) in the LRT arm whereas the risk of local progression was 84% lower with LRT. (more…)
Author Interviews, Prostate Cancer, Race/Ethnic Diversity / 14.01.2014

David M. Albala, MD Associated Medical Professionals of NY, PLLC Syracuse, NY 13210MedicalResearch.com Interview with: David M. Albala, MD Associated Medical Professionals of NY, PLLC Syracuse, NY 13210 MedicalResearch.com: What are the main findings of the study? Dr. Albala: Prostate cancer is the second leading cause of cancer death and American man. Prostate cancer diagnosis and mortality differences between African American and Caucasian populations have been highlighted in the literature. Research has shown that African American males are at a biological predisposition for prostate cancer and that additional socioeconomic and physician-patient educational factors may contribute to a higher mortality rate among this group - over two times greater than that of Caucasian American males. At present the most commonly used to detection tools for prostate cancer are the serum prostatic specific antigen test (PSA) and a digital rectal examination (DRE). These complementary tests provide physicians with an indication of whether to proceed with biopsy for a definitive pathological diagnosis. Despite ongoing disputes regarding the effectiveness of PSA screening as an indicator for prostate cancer, a superior alternative test as yet to become available for men at risk. The American Urological Association (AUA) emphasizes the value of early detection and that sheared decision-making should not be overlooked and that shared decision making should be integral to screening decisions. The AUA urges individuals to personally assess, with their physicians, whether a PSA screen is necessary. Emphasis should be placed on the proper education of African American men who are at increased risk for the disease, as well as on their participation in repeated screening practices for the earliest possible detection of prostate cancer. (more…)
Author Interviews, Cancer Research, Lancet / 14.01.2014

MedicalResearch.com Interview with: Dr Jonathan Banks Programme Manager: The Discovery Research Programme Centre for Academic Primary Care NIHR School for Primary Care Research School of Social and Community Medicine University of Bristol Bristol BS8 2PSDr Jonathan Banks Programme Manager: The Discovery Research Programme Centre for Academic Primary Care NIHR School for Primary Care Research School of Social and Community Medicine University of Bristol Bristol BS8 2PS MedicalResearch.com: What are the main findings of the study? Dr. Banks: We asked members of the public attending their local general practice or primary care centre to consider a series of hypothetical scenarios or vignettes which depicted cancer symptoms, their risk of cancer and the investigative processes involved in testing for cancer. We wanted to measure the point at which the risk of cancer outweighed the burden and inconvenience of testing in relation to lung, colorectal and pancreas cancers. Most people, around 88%, opted for testing even at the lowest risk of cancer which in our vignettes was 1%. Further analyses showed variation between cancers with fewer people opting for testing for colorectal cancer at a low (1%) risk and more people choosing to be tested for all cancers in the 60-69 age group. (more…)
Annals Internal Medicine, Author Interviews, CT Scanning, Lung Cancer / 31.12.2013

dr_harry_j_dekonigMedicalResearch.com Interview with: Harry J de Koning, MD PhD Professor of Public Health & Screening Evaluation Rotterdam, The Netherlands. MedicalResearch.com: What are the main findings of the study? Dr. de Koning: Annual CT screening for lung cancer has a favorable benefit-to-harm ratio for individuals ages 55 through 80 years with 30 or more pack-years’ exposure to smoking. It would lead to 50% (model ranges, 45% to 54) of cases of cancer being detected at an early stage (stage I/II), 575 screenings examinations per lung cancer death averted, a 14% (range, 8.2% to 23.5%) reduction in lung cancer mortality, 497 lung cancer deaths averted, and 5250 life-years gained per the 100 000-member (1950-) cohort. Harms would include 67 550 false-positive test results, 910 biopsies or surgeries for benign lesions, and 190 overdiagnosed cases of cancer (3.7% of all cases of lung cancer [model ranges, 1.4% to 8.3%]), again for a 100 000-member (1950-) cohort. (more…)
Author Interviews, Colon Cancer, Gastrointestinal Disease / 31.12.2013

MedicalResearch.com Interview with: Chia-Hung Kao, MD Graduate Institute of Clinical Medicine Science and School of Medicine, College of Medicine, China Medical University, Taiwan. MedicalResearch.com: What are the main findings of the study? Answer: Colonic diverticular disease and colorectal cancer shared certain characteristics. Some previous studies aimed to identify their epidemiological correlation. However, their results were discrepant and insufficiently strong to draw firm conclusion. In our nationwide population-based retrospective cohort study, we found that the previously diagnosed colonic diverticular disease is not associated with an elevated risk of colorectal cancer after the first year of a diagnosis of colonic diverticular disease (adjusted HR, 0.96). The increased risk in the first year may be due to misclassification and screening effect. (more…)
Author Interviews, Breast Cancer, Nutrition / 21.12.2013

Adana A.M. Llanos, PhD, MPH Assistant Professor, Department of Epidemiology RBHS-School of Public Health Rutgers, The State University of New Jersey Piscataway, NJ 08854MedicalResearch.com Interview with: Adana A.M. Llanos, PhD, MPH Assistant Professor, Department of Epidemiology RBHS-School of Public Health Rutgers, The State University of New Jersey Piscataway, NJ 08854 MedicalResearch.com: What are the main findings of the study? Dr. Llanos: Our longitudinal study examined the effects of both tomato-rich and soy-rich diets in a group of 70 postmenopausal women who participated in the study at The Ohio State University Comprehensive Cancer Center. For 10 weeks, women ate tomato products containing at least 25 milligrams of lycopene daily. For a separate 10-week period, the participants consumed at least 40 grams of soy protein daily. Before each test period began, the women were instructed to abstain from eating both tomato and soy products for two weeks. We examined the dietary intervention effects on hormone biomarkers known to be associated with obesity, namely adiponectin and leptin. After the tomato-rich diet participants' levels of adiponectin climbed nine percent. The effect was slightly stronger in women who had a lower body mass index. (more…)
Author Interviews, Breast Cancer, Chemotherapy / 20.12.2013

MedicalResearch.com Interview with: Prof. Dr. med. Sibylle Loibl MD Unit Head of Medicine & Research Member of Management Board Associate Professor University Frankfurt GBG Forschungs GmbH Neu-Isenburg MedicalResearch.com: What are the main findings of the study? Dr. Loibl: We could demonstrate that patients with a HER2+ primary breast cancer harbouring a PIK3CA mutation are less likely to achieve a pathological complete response after treatment with an anthracycline/taxane containing therapy in combination with trastuzumab and lapatinib, than patients whose tumours does not harbour the mutation (so called wild type). This difference was largest in the group with HER2+, HR + tumours. The pCR rate in this cohort was as low as 6.3%. Looking at the differences in another study with either trastuzumab or lapatinib anti-HER2 treatment is seems as patients with a PIK3CA mutated tumour have a low pCR rate irrespective of the antiHER2 treatment, whereas the patients with a wild type tumour benefit from trastuzumab and the double blockade. (more…)
Author Interviews, Chemotherapy, Compliance / 16.12.2013

Dawn L. Hershman, MD MS Associate Professor of Medicine and MedicalResearch.com Interview with: Dawn L. Hershman, MD MS Associate Professor of Medicine and Epidemiology Leader, Breast Cancer Program Herbert Irving Comprehensive Cancer Center Columbia University Medical Center MedicalResearch.com: What are the main findings of the study? Dr. Hershman: We have found in the past that compliance to 5 years of hormone therapy for the adjuvant treatment of breast cancer is low. While toxicity is a main reason, other factors are also important. Recent studies suggest out of pocket costs are high among cancer patients. We evaluated the change in adherence to hormone therapy after the introduction of generic Aromatase inhibitors. We found that discontinuation decreased and adherence increased with generic aromatase inhibitors compared to brand name. we found that higher co-payments were associated with decreased adherence and increased discontinuation. We also found that patients in the highest income group were more likely to be adherent to hormone therapy. (more…)
Author Interviews, Prostate Cancer, Race/Ethnic Diversity / 11.12.2013

Dr David P. Turner PhD Assistant Professor Director of shRNA Technology Medical University of South Carolina Dept of Pathology & Lab Medicine Charleston SC 29425MedicalResearch.com Interview with: Dr David P. Turner PhD Assistant Professor, Director of shRNA Technology Medical University of South Carolina Dept of Pathology & Lab Medicine Charleston SC 29425 MedicalResearch.com: What are the main findings of the study? Dr. Turner: Our research has identified a potential mechanistic link between sugar derived metabolites and cancer associated pathways which may be a biological consequence of the socioeconomic and biological factors that are known to drive cancer health disparity. African Americans develop and die more frequently of cancer than any other population in the US. We examined the levels of reactive metabolites known as advanced glycation end-products, or AGEs for short, in serum and tumor samples from African American and Non-Hispanic White prostate cancer patients. In both the serum and tumor tissue, the levels of AGE metabolites were consistently higher in the African American prostate cancer patients than their White counterparts. AGE functions as a ligand for the receptor for AGEs, or RAGE for short. We also identified that RAGE protein levels were higher in African Americans with prostate cancer. (more…)
Author Interviews, Chemotherapy, Gastrointestinal Disease, Hepatitis - Liver Disease, MD Anderson / 10.12.2013

Harrys A. Torres, MD, FACP Assistant Professor Director of Hepatitis C Clinic Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer CenterMedicalResearch.com Interview with: Harrys A. Torres, MD, FACP Assistant Professor, Director of Hepatitis C Clinic Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer Center MedicalResearch.com: What are the main findings of the study? Dr. Torres: The main findings of the study were that patients with hepatitis C virus (HCV) infection who were successfully treated with antivirals and attained sustained virologic response (SVR) did not have a relapse of HCV infection after receiving immunosuppressive chemotherapy for cancer. Patients in the study received different chemotherapeutic agents, including rituximab and systemic corticosteroids. Durability of SVR was maintained up to 14 years after chemotherapy in cancer patients. (more…)
Author Interviews, Breast Cancer, Radiology / 06.12.2013

Nicholas M Perry MD London Breast InstituteMedicalResearch.com Interview with: Nicholas M Perry MD London Breast Institute MedicalResearch.com: What are the main findings of your study? Dr. Perry: The main findings from the study were that automated density readings outperformed radiologists, and that women under the age of 50 had a more significant risk of breast cancer from higher breast density. Also, and quite surprising was the appearance of a completely different age- density pattern in women with breast cancer. Whereas the women in the study without cancer showed a normal and steady decline in breast density with age, those with cancer showed a completely different curvi-linear pattern, which was evident in women as young as 30. The message is that breast density remains an important factor for both the current breast screening methodologies, and for future research into investigation and management. (more…)
Author Interviews, Breast Cancer, Nutrition, Pediatrics, University of Michigan / 01.12.2013

Richard Schwartz, Ph.D. Professor, Associate Dean for Graduate Academic and Student Affairs College of Natural Science Michigan State University Department of Microbiology and Molecular Genetics Michigan State University East Lansing, MI 48824-4320MedicalResearch.com Interview with: Richard Schwartz, Ph.D. Professor, Associate Dean for Graduate Academic and Student Affairs College of Natural Science Michigan State University Department of Microbiology and Molecular Genetics Michigan State University East Lansing, MI 48824-4320 MedicalResearch.com: What are the main findings of the study? Dr. Schwartz: The main finding is that exposure to a high fat diet from the age of puberty onwards hastened the development of chemical carcinogen-induced breast cancer in absence of weight gain. We also found that prior to the appearance of any tumors, we could detect changes in the mammary gland that included increased cellular proliferation, increased vascularity, and changes in immune function. (more…)
Author Interviews, Colon Cancer, Gastrointestinal Disease / 25.11.2013

Li-Shu Wang, PhD Department of Medicine, Medical College of Wisconsin, Milwaukee, WisconsinMedicalResearch.com Interview with: Li-Shu Wang, PhD Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin MedicalResearch.com: What are the main findings of the study? Answer: Ulcerative colitis (UC) is frequently an intermediate step to colon cancer. The interleukin-10 knock-out (KO) mouse is a genetic model of this progression. We have now shown that KO mice fed 5% black raspberries (BRBs) had significantly less colonic ulceration as compared to KO mice that consumed the control diet. Dysfunction of the Wnt signaling pathway is a key event in UC-associated colon carcinogenesis. We investigated the effects of BRBs on the Wnt pathway and found that the BRB-fed KO mice exhibited significantly decreased promoter methylation of Wnt antagonists and a significantly lower level of β-catenin nuclear translocation. Our results suggest that BRBs inhibit colonic ulceration partly through inhibiting aberrant epigenetic events that dysregulate Wnt signaling. (more…)
Author Interviews, Breast Cancer, Chemotherapy, Lancet, MD Anderson / 24.11.2013

Dr. Kelly K. Hunt, M.D., F.A.C.S. Professor, Department of Surgical Oncology, Division of Surgery Chief, Breast Surgical Oncology Section, Department of Surgical Oncology The University of Texas MD Anderson Cancer Center, Houston, TXMedicalResearch.com Interview with: Dr. Kelly K. Hunt, M.D., F.A.C.S. Professor, Department of Surgical Oncology, Division of Surgery Chief, Breast Surgical Oncology Section, Department of Surgical Oncology The University of Texas MD Anderson Cancer Center, Houston, TX MedicalResearch.com: What are the main findings of the study? Dr. Hunt: The primary endpoint of the Z1041 trial was the proportion of patients who had pathological complete response in the breast, defined as the percentage of women who started the neoadjuvant treatment with no histological evidence of disease in the breast at surgery. We found that high pathologic response rates were observed in both treatment groups with similar cardiac safety profiles in both arms of the trial. Specifically, 56.5% of patients in the sequential group (fluorouracil, epirubicin and cyclophosphamide on day one of a 21-day cycle for four cycles followed by paclitaxel plus trastuzumab weekly for 12 weeks) had a complete pathological response versus 54.2% of the patients who received the concurrent regimen (paclitaxel and trastuzumab weekly for 12 weeks followed by fluorouracil, epirubicin and cyclophosphamide on day one of a 21-day cycle with trastuzumab on days one, eight and 15 of the 21-day cycle for four cycles). The difference in pathologic complete response rates between the treatment arms was not statistically significant. Cardiac safety was a secondary endpoint of the trial and we found that both regimens had acceptable cardiac safety profiles. (more…)
Author Interviews, Genetic Research, Nature, Thyroid / 24.11.2013

Yuri E. Nikiforov, M.D., Ph.D. Professor of Pathology Vice Chair for Molecular Pathology Director, Division of Molecular & Genomic Pathology Department of Pathology University of Pittsburgh Pittsburgh, PA 15213MedicalResearch.com Interview Yuri E. Nikiforov, M.D., Ph.D. Professor of Pathology, Vice Chair for Molecular Pathology Director, Division of Molecular & Genomic Pathology Department of Pathology, University of Pittsburgh Pittsburgh, PA MedicalResearch.com: What are the main findings of the study? Dr. Nikiforov: This is examined temporal changes in mutational profiles and standardized histopathologic features of thyroid cancer in the U.S. over the last four decades. It showed a significant change in molecular profiles of thyroid cancer during the past 40 years as it determined two major trends in changing the mutational make-up of thyroid cancer: a rapid increase in the prevalence of RAS mutations, particularly for the last 10 years, and continuous decrease in frequency of RET/PTC rearrangement. The rising incidence of RAS mutations points to new and more recent etiologic factors, probably of a chemical or dietary nature. The decreasing incidence of RET/PTC rearrangements, a known marker of high-dose environmental and medical radiation, suggest that the impact of ionizing radiation, at least as related to high-dose environmental exposures and historical patterns of radiation treatment for benign conditions, is diminishing. (more…)
Antioxidants, Author Interviews, Brigham & Women's - Harvard, Medical Research Centers, Nature, Nutrition, Pancreatic / 23.11.2013

MedicalResearch.com Interview with: dr_ying_baoYing Bao, MD, ScD Department of Medicine, Brigham and Women's Hospital and Harvard Medical School Boston, MA. MedicalResearch.com: What are the main findings of the study? Dr. Bao: Frequent nut consumption is inversely associated with risk of pancreatic cancer in women, independent of other potential risk factors for pancreatic cancer. (more…)
Author Interviews, Cancer Research, Lymphoma, NEJM / 22.11.2013

Kieron M. Dunleavy, M.D. Metabolism Branch Lymphoma Therapeutics Section Staff Clinician Center for Cancer Research National Cancer Institute Bethesda, MD 20892MedicalResearch.com Interview with Kieron M. Dunleavy, M.D. Metabolism Branch Lymphoma Therapeutics Section Center for Cancer Research National Cancer Institute, Bethesda, MD 20892 MedicalResearch.com: What are the main findings of the study? Dr. Dunleavy: We found that low-intensity therapy was highly effective in Burkitt's lymphoma and cured over 95% of patients with the disease. (more…)
Author Interviews, Colon Cancer, Nature, Race/Ethnic Diversity, Stanford / 18.11.2013

 James Murphy, M.D. Assistant Professor Department of Radiation Medicine and Applied Sciences Center for Advanced Radiotherapy Technologies UC San Diego Moores Cancer Center 3855 Health Sciences Drive La Jolla, CA 92093MedicalResearch.com Interview with: James Murphy, M.D. Assistant Professor, Department of Radiation Medicine and Applied Sciences, Center for Advanced Radiotherapy Technologies ,UC San Diego Moores Cancer Center La Jolla, CA 92093 MedicalResearch.com: What are the main findings of the study? Dr. Murphy: This study evaluated racial disparity in metastatic colorectal cancer. In a large population-based cohort we found of over 11,000 patients we found that black patients were less likely to be seen in consultation by a cancer specialist, and were less likely to receive treatment with chemotherapy, surgery, or radiation. Furthermore, we found that this disparity in treatment accounted for a substantial portion of the race-based differences between black and white patients. (more…)
Author Interviews, Breast Cancer, Lancet, Radiation Therapy / 11.11.2013

Prof Jayant S Vaidya PhD Clinical Trials Group, Division of Surgery and Interventional Science University College London, London, UKMedicalResearch.com Interview with: Prof Jayant S Vaidya PhD Clinical Trials Group, Division of Surgery and Interventional Science University College London, London, UK MedicalResearch.com: What are the main findings of the study? Dr. Vaidya: The main findings are
  • a) these are longer term results that have confirmed our original publication in 201
  • (b) We found that when TARGIT intraoperative radiotherapy is given at the time of lumpectomy for breast cancer, the local control and survival from breast cancer is similar to several weeks of whole breast radiotherapy
  • c) we also found that with TARGIT there are significantly fewer deaths from other causes - i.e., fewer deaths from cardiovascular causes and other cancers
(more…)
Author Interviews, Cancer Research, OBGYNE, Pediatrics / 09.11.2013

Alastair Sutcliffe M.D., Ph.D. From the Institute of Child Health University College LondonMedicalResearch.com Interview with: Alastair Sutcliffe M.D., Ph.D. From the Institute of Child Health University College London   MedicalResearch.com: What are the main findings of the study? Dr. Sutcliffe: Good NEWS for couples who need assisted conception. All the births (106,000) from Great Britain over 18 years were linked to the National Childhood Cancer Registry from the Human Fertilisation and Embryology Authority (which has recorded all births sine 1991 by law.)Those children who showed up on both registries, had IVF conception and childhood cancer. We predicted the number we would expect from the known national childhood cancer rates. We found ALMOST IDENTICAL rates 108 in our group and 109 predicted. NO INCREASED RISK OF CANCER AFTER IVF CONCEPTION IN OFFSPRING. (more…)
Author Interviews, Breast Cancer / 07.11.2013

Mila Donker, MD Resident in Radiation Oncology Study monitor EORTC 10981-22023 AMAROS trialMedicalResearch.com Interview with: Mila Donker, MD Resident in Radiation Oncology Study monitor EORTC 10981-22023 AMAROS trial The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands MedicalResearch.com: What are the main findings of the study? Dr. Donker: Results of EORTC trial 10853 which were recently published in the Journal of Clinical Oncology showed that breast conserving treatment combined with radiotherapy reduces the risk of local recurrence in women with ductal carcinoma in situ (DCIS). Between 1986 and 1996, this phase III EORTC trial 10853 randomized 1010 women with complete local excision of DCIS to no further treatment (503 patients) or radiotherapy (507 patients). The risk of any local recurrence was found to be reduced by 48% in the patients who also received radiotherapy. The 15-year local recurrence-free rate was 69% for the group of patients receiving breast conserving surgery alone, but this increased to 82% for the group of patients who also received radiotherapy, and the 15-year invasive local recurrence-free rate was 84% versus 90%, respectively. (more…)
Author Interviews, Cancer Research, Chemotherapy / 06.11.2013

MedicalResearch.com Interview with: Dr. Shuichi Hironaka, MD Clinical Trial Promotion Department, Chiba Cancer Center 666-2 Nitona-cho Chuo-ku Chiba-shi Chiba, 260-8717 Japan MedicalResearch.com: What are the main findings of the study? Dr. Hironaka: This is the first randomized phase III trial comparing paclitaxel and irinotecan in second-line chemotherapy for advanced gastric cancer. This study showed that no statistically significant difference was observed between paclitaxel and irinotecan for overall survival. However, both are reasonable second-line treatment options for advanced gastric cancer. (more…)
Cancer Research, MD Anderson, Radiation Therapy / 01.11.2013

Steven J. Frank, M.D., associate professor of Radiation Oncology at The University of Texas MD Anderson Proton Therapy CenterMedicalResearch.com Interview with: Steven J. Frank, M.D., associate professor of Radiation Oncology at The University of Texas MD Anderson Proton Therapy Center discusses the findings of his latest study, “Gastrostomy Tubes Decrease by Over 50% with Intensity Modulated Proton Therapy during the Treatment of Oropharyngeal Cancer Patients.” MedicalResearch.com: What are the main findings of the study? Dr. Frank: The study found that the use of feeding tubes in oropharyngeal carcinoma (OPC) cancer patients treated with intensity modulated proton therapy (IMPT) decreased by more than 50% percent compared to patients treated with intensity modulated radiation therapy (IMRT). This suggests that proton therapy may offer vital quality of life benefits for patients with tumors occurring at the back of the throat. Of the 50 OPC patients enrolled in the study:
  • Twenty-five patients were treated with IMPT and 25 received IMRT.
  • Five patients treated with IMPT required the use of feeding tubes (20%) compared to 12 patients treated with IMRT (48%).
  • IMPT patients were spared from serious side effects, usually a result of IMRT, such as loss of taste, vomiting, nausea, pain, mouth and tongue ulcers, dry mouth, fatigue, and swallowing difficulty.
  • IMPT patients could better sustain their nutrition and hydration levels, often leading to faster recovery during and after treatment.
IMPT is an advanced form of proton radiation therapy and a treatment currently only offered in North America at The University of Texas MD Anderson Proton Therapy Center. It delivers protons to the most complicated tumors by focusing a narrow proton beam and essentially “painting” the radiation dose onto the tumor layer by layer. Unlike IMRT, which destroys both cancerous and healthy cells, IMPT has the ability to destroy cancer cells while sparing surrounding healthy tissue from damage. Therefore, important quality of life outcomes such as neurocognitive function, vision, swallowing, hearing, taste and speech can be preserved in head and neck patients. (more…)
Author Interviews, Prostate Cancer, Weight Research / 01.11.2013

MedicalResearch.com Interview with: Reina Haque, PhD, MPH Research scientist, Kaiser Permanente Department of Research & Evaluation MedicalResearch.com: What are the main findings of the study? Answer: The main study findings are that men who are overweight or obese when they are diagnosed with prostate cancer are more likely to die from the disease than men who are of healthy weight. In patients with more aggressive forms of prostate cancer, the researchers also found an even stronger correlation between obesity and mortality. The study was restricted to patients undergoing surgical treatment for prostate cancer, rather than other treatments such as radiation or hormone therapy. (more…)
Author Interviews, Melanoma / 22.10.2013

Jeffrey Weber, M.D, Ph.D. Senior Researcher, Moffitt Cancer Center Tampa, FloridaMedicalResearch.com Interview with: Jeffrey Weber, M.D, Ph.D. Senior Researcher, Moffitt Cancer Center Tampa, Florida MedicalResearch.com: What are the main findings of the study? Dr. Weber: That the PD-1 blocking antibody nivolumab has a 25% ORR with long duration of response in ipilimumab refractory patients, and that patients with prior grade 3-4 ipilimumab related immune related side effects may be safely treated with nivolumab without reproducing the prior IPI related side effects. (more…)